Table 1.
Number of patients – no. | 256 |
Age – years | |
Median (IQR) | 75 (63–81) |
Female – no. (%) | 157 (61.3) |
BMI | |
Median (range) | 22.6 (14.87–54.82) |
ECOG performance score – value | |
Median (IQR) | 3 (1–4) |
Comorbidities – no. (%) | |
Cardiovascular | 154 (60.2) |
Gastrointestinal (except CDI) | 90 (35.2) |
Endocrinological | 81 (31.6) |
Nephrological | 75 (29.3) |
Hematological/oncological | 68 (26.6) |
Pulmonary | 52 (20.3) |
Neurological | 37 (14.5) |
Psychiatric | 34 (13.3) |
Orthopedic | 23 (9.0) |
Rheumatological | 15 (5.9) |
Urological | 10 (3.9) |
Othera | 28 (10.9) |
None | 12 (4.7) |
Transplantation – no. (%) | |
Solid organ | 8 (3.1) |
Allogenic stem cell | 4 (1.6) |
Immunosuppression – no. (%) | |
Chemotherapy | 18 (7.0) |
Other immunosuppressive medication | 48 (18.8) |
CDI recurrences before FMT – no. | |
Median (IQR) | 3 (2–4) |
Antibiotic pre-treatmentb – no. (%) | 237 (92.6) |
Sequential Metro+Vanco | 91 (35.5) |
Sequential Metro+Vanco+Fidaxo | 72 (28.1) |
Vancomycin only | 31 (12.1) |
Sequential Fidaxo+Vanco | 16 (6.3) |
Sequential Metro+Vanco+Rifax | 11 (4.3) |
Otherc | 16 (6.3) |
Unknown | 19 (7.4) |
BMI = body mass index; CDI = Clostridioides difficile infection; ECOG = Eastern Cooperative Oncology Group (range 0–5); IQR = interquartile range; SD = standard deviation.
Other: dermatological n = 5 (2.0%), ophthalmological n = 5 (2.0%), immunosuppressive n = 6 (2.3%), infective n = 4 (1.6%), coagulative n = 3 (1.2%), gynecological n = 4 (1.6%), otorhinolaryngological n = 1 (0.4%).
Antibiotic pre-treatment: any kind of antibiotic ever given to the patient during previous CDI episodes
Other: metronidazole only n = 7, sequential metronidazole + vancomycin + fidaxomicin + rifaximin n = 3, fidaxomicin only n = 2, sequential rifaximin + vancomycin n = 1, sequential metronidazole + vancomycin + fidaxomicin + rifaximin + tigecycline n = 1, drug sequence unknown n = 2.